WinstonWınston
Coloplast A/S logo

Coloplast A/S

CLPBY
57
Medical - Instruments & Supplies · Healthcare
Price
$6.80
+0.19 (+2.87%)
Market Cap
$15.32B
Exchange
Other OTC
Winston Score
57
Winston is curious
A decent business — some strong pillars, some weaker.
Data as of Aug 9, 2026 · filings through Mar 31, 2026

Share count rising — dilution

+5.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 2.13B (2021) → 2.25B (2025)

Coloplast is a Danish medical device company that makes products for people with intimate health conditions — things like ostomy bags (for people who've had bowel surgery), catheters, wound care supplies, and continence products. Its customers are mostly patients, hospitals, and home care providers across the world. Coloplast is one of the largest companies globally focused specifically on these types of sensitive, chronic-care medical needs.

The company earns money by selling its medical supplies directly and through healthcare distributors, with many patients relying on its products on a recurring, long-term basis — which creates steady, repeat revenue. Coloplast operates in over 40 countries, with strong positions in Europe and growing sales in North America and emerging markets. Its moat comes from deep clinical relationships, specialized product design, and the fact that patients rarely switch brands once they find something that works. The main risk is pricing pressure from government healthcare systems and competition from lower-cost rivals in key markets.

Winston Score History

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
42.9%
Healthy — 42.9% gross margin
Operating Margin
25.4%
Excellent — 25.4% operating margin
ROCE
5.0%
Weak — 5.0% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-4.5%
Shrinking sales (-4.5% YoY)
EPS YoY
-54.5%
Earnings shrinking (-54.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
367%
Turns 367% of profit into real cash
FCF Margin
22.8%
Converts sales into free cash efficiently (22.8%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
1.82
Elevated debt (1.82)
Interest Cover
7.61x
Adequate interest coverage (7.6x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
7.4x
Attractive valuation — P/E 7.4

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward
+5.1
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (7.4 → 2.3)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend Yield
5.26%
Healthy income — 5.26% yield

Generous yield. Worth checking whether the payout is sustainable.

Dividend Growth
+14.3%
Dividend growing fast (14.3% YoY)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial